EE03014B1 - Pikendatud ja kontrollitud vabanemisega peptiidi sisaldav ravimaine kompositsioon ja selle valmistamismeetod - Google Patents

Pikendatud ja kontrollitud vabanemisega peptiidi sisaldav ravimaine kompositsioon ja selle valmistamismeetod

Info

Publication number: EE03014B1
Authority: EE; Estonia
Prior art keywords: sustained; making; same; controlled release; drug composition
Prior art date: 1991-07-22

Application number

EE9400282A

Other languages

English (en)

Inventor

Heimgartner Fr�d�ric

Orsolini Piero

Original Assignee

Asta Medica Aktiengesellschaft

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-07-22

Filing date

1994-11-21

Publication date

1997-08-15

1994-11-21 Application filed by Asta Medica Aktiengesellschaft filed Critical Asta Medica Aktiengesellschaft

1997-08-15 Publication of EE03014B1 publication Critical patent/EE03014B1/et

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2257—Prolactin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Endocrinology (AREA)
Zoology (AREA)
Organic Chemistry (AREA)
Diabetes (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Cardiology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Reproductive Health (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Manufacturing Of Micro-Capsules (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

EE9400282A 1991-07-22 1994-11-21 Pikendatud ja kontrollitud vabanemisega peptiidi sisaldav ravimaine kompositsioon ja selle valmistamismeetod EE03014B1 (et)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CH2178/91A CH683149A5 (fr)	1991-07-22	1991-07-22	Procédé pour la préparation de microsphères en matériau polymère biodégradable.

Publications (1)

Publication Number	Publication Date
EE03014B1 true EE03014B1 (et)	1997-08-15

Family

ID=4227716

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EE9400282A EE03014B1 (et)	1991-07-22	1994-11-21	Pikendatud ja kontrollitud vabanemisega peptiidi sisaldav ravimaine kompositsioon ja selle valmistamismeetod

Country Status (40)

Country	Link
US (2)	US5445832A (et)
JP (2)	JP2842736B2 (et)
KR (1)	KR930702018A (et)
CN (1)	CN1054543C (et)
AT (2)	AT403348B (et)
AU (2)	AU651711B2 (et)
BE (2)	BE1005697A5 (et)
BR (1)	BR9205375A (et)
CA (2)	CA2074322C (et)
CH (2)	CH683149A5 (et)
CZ (1)	CZ287585B6 (et)
DE (3)	DE4223282A1 (et)
DK (2)	DK176218B1 (et)
EE (1)	EE03014B1 (et)
ES (2)	ES2037621B1 (et)
FI (2)	FI105318B (et)
FR (2)	FR2680109B1 (et)
GB (2)	GB2257909B (et)
GR (2)	GR1002548B (et)
HR (1)	HRP920229A2 (et)
HU (1)	HU218203B (et)
IE (2)	IE69967B1 (et)
IL (2)	IL102591A (et)
IT (2)	IT1259892B (et)
LU (2)	LU88150A1 (et)
MX (1)	MX9204268A (et)
NL (2)	NL194576C (et)
NO (2)	NO304136B1 (et)
NZ (1)	NZ243643A (et)
PH (1)	PH31564A (et)
PL (1)	PL169387B1 (et)
PT (2)	PT100713B (et)
RU (1)	RU2103994C1 (et)
SE (2)	SE512609C2 (et)
SI (1)	SI9200152B (et)
SK (1)	SK280612B6 (et)
TW (1)	TW260610B (et)
UA (1)	UA35569C2 (et)
WO (1)	WO1993001802A1 (et)
ZA (2)	ZA925486B (et)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH683149A5 (fr) *	1991-07-22	1994-01-31	Debio Rech Pharma Sa	Procédé pour la préparation de microsphères en matériau polymère biodégradable.
FR2693905B1 (fr) *	1992-07-27	1994-09-02	Rhone Merieux	Procédé de préparation de microsphères pour la libération prolongée de l'hormone LHRH et ses analogues, microsphères et formulations obtenues.
US5981719A (en)	1993-03-09	1999-11-09	Epic Therapeutics, Inc.	Macromolecular microparticles and methods of production and use
US6090925A (en)	1993-03-09	2000-07-18	Epic Therapeutics, Inc.	Macromolecular microparticles and methods of production and use
US5681811A (en) *	1993-05-10	1997-10-28	Protein Delivery, Inc.	Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US6191105B1 (en)	1993-05-10	2001-02-20	Protein Delivery, Inc.	Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
DE4320201A1 (de) *	1993-06-18	1995-01-12	Asta Medica Ag	Verwendung von Cetrorelix und weiteren Nona- und Dekapeptiden zur Herstellung eines Arzneimittels zur Bekämpfung von Aids und zur Wachstumsstimulation
US6087324A (en) *	1993-06-24	2000-07-11	Takeda Chemical Industries, Ltd.	Sustained-release preparation
DE4342092B4 (de) *	1993-12-09	2007-01-11	Zentaris Gmbh	Langwirkende Injektionssuspension und Verfahren zur Herstellung
CA2224381A1 (en)	1995-06-27	1997-01-16	Takeda Chemical Industries, Ltd.	Method of producing sustained-release preparation
US5931809A (en)	1995-07-14	1999-08-03	Depotech Corporation	Epidural administration of therapeutic compounds with sustained rate of release
DE19545257A1 (de)	1995-11-24	1997-06-19	Schering Ag	Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln
KR0162872B1 (ko) *	1996-04-01	1998-12-01	김은영	용매추출법을 이용한 생분해성 고분자 미립구의 개선된 제조방법 및 이를 이용한 국소염증 질환 치료용 미립구의 제조방법
US20020111603A1 (en) *	1996-12-02	2002-08-15	Societe De Conseils De Recherches Et D'application	Device for local administration of solid or semi-solid formulations and delayed-release formulations for proposal parental administration and preparation process
WO1998032423A1 (en) *	1997-01-29	1998-07-30	Takeda Chemical Industries, Ltd.	Sustained-release microspheres, their production and use
MY118835A (en) *	1997-04-18	2005-01-31	Ipsen Pharma Biotech	Sustained release compositions and the process for their preparation
CA2324254C (en) *	1998-03-18	2005-01-04	University Technology Corporation	Sustained-release composition including amorphous polymer
US6613358B2 (en)	1998-03-18	2003-09-02	Theodore W. Randolph	Sustained-release composition including amorphous polymer
SE9801288D0 (sv) *	1998-04-14	1998-04-14	Astra Ab	Vaccine delivery system and metod of production
US6270700B1 (en)	1998-07-23	2001-08-07	Societe De Conseils De Recherches Et D'applications Scientifiques, Sas	Encapsulation of water soluble peptides
US20070009605A1 (en) *	1998-07-23	2007-01-11	Ignatious Francis X	Encapsulation of water soluble peptides
EP1240896A3 (en) *	1998-07-23	2003-03-26	Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S.	Encapsulation of water soluble peptides
WO2000004916A1 (en) *	1998-07-23	2000-02-03	Societe De Conseils De Recherches Et D'applications Scientifiques Sas	Encapsulation of water soluble peptides
US6703381B1 (en)	1998-08-14	2004-03-09	Nobex Corporation	Methods for delivery therapeutic compounds across the blood-brain barrier
GB2344519B (en) *	1998-12-07	2004-05-19	Johnson & Johnson Medical Ltd	Sterile therapeutic compositions
IT1304152B1 (it) *	1998-12-10	2001-03-08	Mediolanum Farmaceutici Srl	Composizioni comprendenti un peptide ed acido polilattico-glicolicoatte alla preparazione di impianti sottocutanei aventi un prolungato
US6682724B2 (en)	1999-02-23	2004-01-27	Arch Chemcials, Inc.	Sonic method of enhancing chemical reactions to provide uniform, non-agglomerated particles
US6204308B1 (en)	1999-03-01	2001-03-20	Novartis Ag	Organic compounds
US6317623B1 (en) *	1999-03-12	2001-11-13	Medrad, Inc.	Apparatus and method for controlling contrast enhanced imaging procedures
AU3556400A (en)	1999-03-17	2000-10-04	Novartis Ag	Pharmaceutical compositions
EP1044683A1 (en)	1999-04-15	2000-10-18	Debio Recherche Pharmaceutique S.A.	One-step dispersion method for the microencapsulation of water soluble substances
ES2169980B1 (es)	1999-12-17	2003-11-01	Lipotec Sa	Microcapsulas para la liberacion prolongada de farmacos.
US6309454B1 (en)	2000-05-12	2001-10-30	Johnson & Johnson Medical Limited	Freeze-dried composite materials and processes for the production thereof
AU2002232824A1 (en)	2000-12-21	2002-07-01	Inhale Therapeutic Systems, Inc.	Induced phase transition method for the production of microparticles containing hydrophobic active agents
US20060003012A9 (en) *	2001-09-26	2006-01-05	Sean Brynjelsen	Preparation of submicron solid particle suspensions by sonication of multiphase systems
IL160570A0 (en) *	2001-09-26	2004-07-25	Baxter Int	Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
US7112340B2 (en) *	2001-10-19	2006-09-26	Baxter International Inc.	Compositions of and method for preparing stable particles in a frozen aqueous matrix
KR100885070B1 (ko) *	2002-05-08	2009-02-25	재단법인서울대학교산학협력재단	Ｐｌｇａ에 특이적으로 부착하는 올리고 펩타이드
CN1732012A (zh) *	2002-12-27	2006-02-08	迪奥贝克斯公司	用于预防和控制胰岛素诱发的低血糖的组合物和方法
US7655618B2 (en)	2002-12-27	2010-02-02	Diobex, Inc.	Compositions and methods for the prevention and control of insulin-induced hypoglycemia
BRPI0407071B8 (pt)	2003-01-28	2021-05-25	Ironwood Pharmaceuticals Inc	peptídeo purificado, seu método de produção e composição farmacêutica para o tratamento de distúrbios gastrointestinais
US7772188B2 (en)	2003-01-28	2010-08-10	Ironwood Pharmaceuticals, Inc.	Methods and compositions for the treatment of gastrointestinal disorders
JP2007525442A (ja) *	2003-03-05	2007-09-06	ピーアールファーマシューティカルズ，インコーポレイテッド	オキシトシン制御放出処方物およびオキシトシン制御放出処方物を使用する方法
US6987111B2 (en) *	2003-08-06	2006-01-17	Alkermes Controlled Therapeutics, Ii	Aripiprazole, olanzapine and haloperidol pamoate salts
PT1682537E (pt)	2003-11-05	2012-06-20	Sarcode Bioscience Inc	Moduladores de adesão celular
KR101276754B1 (ko)	2004-07-19	2013-06-19	바이오콘 리미티드	인슐린―올리고머 접합체，제형 및 이들의 용도
PT1781264E (pt)	2004-08-04	2013-10-16	Evonik Corp	Métodos para o fabrico de dispositivis de administração e dispositivos para a mesma
ES2255426B1 (es) *	2004-10-19	2007-08-16	Gp Pharm, S.A.	Formulacion farmaceutica que comprende microcapsulas de estatinas suspendidas en ester alquilicos de acidos grasos poliinsaturados (pufa).
EP1674082A1 (de)	2004-12-22	2006-06-28	Zentaris GmbH	Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel
WO2006078903A1 (en) *	2005-01-21	2006-07-27	Matthews Richard H	Radiosensitizer formulations comprising nitrohistidine derivatives
AU2006241072A1 (en) *	2005-04-25	2006-11-02	Amgen Inc.	Biodegradable peptide sustained release compositions containing porogens
WO2006125119A1 (en) *	2005-05-17	2006-11-23	Sarcode Corporation	Compositions and methods for treatment of eye disorders
BRPI0612071A2 (pt) *	2005-06-14	2010-10-19	Baxter Int	formulações farmacêuticas para minimizar interações entre fármacos
JP2009516003A (ja) *	2005-11-15	2009-04-16	バクスター・インターナショナル・インコーポレイテッド	リポキシゲナーゼ阻害剤の組成物
AR058591A1 (es) *	2005-12-22	2008-02-13	Novartis Ag	Formulacion de liberacion sostenida que comprende octreotida y dos o mas polimeros de polilactido-coglicolido
EP1983917B1 (en)	2006-01-27	2014-06-25	Spinal Ventures, LLC	Low pressure delivery system for delivering a solid and liquid mixture into a target site for medical treatment
KR100722607B1 (ko) *	2006-05-11	2007-05-28	주식회사 펩트론	분산성 및 주사 투여능이 향상된 서방성 미립구의 제조방법
US7403325B2 (en) *	2006-05-19	2008-07-22	Xerox Corporation	Electrophoretic display device
US7858663B1 (en)	2007-10-31	2010-12-28	Pisgah Laboratories, Inc.	Physical and chemical properties of thyroid hormone organic acid addition salts
US20080293695A1 (en)	2007-05-22	2008-11-27	David William Bristol	Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance
US7718649B1 (en)	2006-11-10	2010-05-18	Pisgah Labs, Inc.	Physical states of a pharmaceutical drug substance
US8211905B1 (en)	2007-05-22	2012-07-03	Pisgah Laboratories, Inc.	Opioid salts and formulations exhibiting anti-abuse and anti-dose dumping properties
US8039461B1 (en)	2006-11-10	2011-10-18	Pisgah Laboratories, Inc.	Physical states of a pharmaceutical drug substance
US10183001B1 (en)	2007-05-22	2019-01-22	Pisgah Laboratories, Inc.	Opioid and attention deficit hyperactivity disorder medications possessing abuse deterrent and anti-dose dumping safety features
US20080293814A1 (en) *	2007-05-22	2008-11-27	Deepak Tiwari	Concentrate esmolol
US8426467B2 (en) *	2007-05-22	2013-04-23	Baxter International Inc.	Colored esmolol concentrate
US9421266B2 (en)	2007-05-22	2016-08-23	Pisgah Laboratories, Inc.	Safety of pseudoephedrine drug products
US8329720B1 (en)	2007-05-22	2012-12-11	Pisgah Laboratories, Inc.	Opioid salts and formulations exhibiting abuse deterrent and anti-dose dumping properties
US8722736B2 (en) *	2007-05-22	2014-05-13	Baxter International Inc.	Multi-dose concentrate esmolol with benzyl alcohol
US20100120694A1 (en)	2008-06-04	2010-05-13	Synergy Pharmaceuticals, Inc.	Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
US7879802B2 (en)	2007-06-04	2011-02-01	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en)	2007-06-04	2015-03-03	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
AP3000A (en) *	2007-06-06	2014-10-31	Debiopharm Res & Mfg Sa	Slow release pharmaceutical composition made of microparticles
MX2010003979A (es)	2007-10-16	2010-06-02	Biocon Ltd	Composicion farmaceutica oralmente administrable y proceso para su preparacion.
AU2008317473B2 (en)	2007-10-19	2014-07-17	Bausch + Lomb Ireland Limited	Compositions and methods for treatment of diabetic retinopathy
US8728528B2 (en)	2007-12-20	2014-05-20	Evonik Corporation	Process for preparing microparticles having a low residual solvent volume
US8883863B1 (en)	2008-04-03	2014-11-11	Pisgah Laboratories, Inc.	Safety of psuedoephedrine drug products
WO2009139817A2 (en)	2008-04-15	2009-11-19	Sarcode Corporation	Crystalline pharmaceutical and methods of preparation and use thereof
US20090258069A1 (en) *	2008-04-15	2009-10-15	John Burnier	Delivery of LFA-1 antagonists to the gastrointestinal system
ES2624828T3 (es)	2008-07-16	2017-07-17	Synergy Pharmaceuticals Inc.	Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
US20100062057A1 (en) *	2008-09-10	2010-03-11	Pronova BioPharma Norge AS.	Formulation
US11395811B2 (en)	2009-03-09	2022-07-26	Pronova Biopharma Norge As	Compositions comprising a fatty acid oil mixture comprising EPA and DHA in free acid form and a surfactant, and methods and uses thereof
WO2011050175A1 (en) *	2009-10-21	2011-04-28	Sarcode Corporation	Crystalline pharmaceutical and methods of preparation and use thereof
ES2364011B1 (es)	2009-11-20	2013-01-24	Gp Pharm, S.A.	Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares.
ES2363964B1 (es)	2009-11-20	2012-08-22	Gp Pharm, S.A.	Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados.
ES2363965B1 (es)	2009-11-20	2013-01-24	Gp Pharm S.A.	Cápsulas de principios activos betabloqueantes y ésteres de ácidos grasos poliinsaturados.
SG181446A1 (en)	2009-12-23	2012-07-30	Defiante Farmaceutica Sa	Combination composition useful for treating cardiovascular diseases
ES2385240B1 (es)	2010-07-26	2013-09-23	Gp-Pharm, S.A.	Cápsulas de principios activos farmacéuticos y ácidos grasos poliinsaturados para el tratamiento de enfermedades de la próstata.
US9616097B2 (en)	2010-09-15	2017-04-11	Synergy Pharmaceuticals, Inc.	Formulations of guanylate cyclase C agonists and methods of use
MX362218B (es)	2011-05-04	2019-01-09	Balance Therapeutics Inc	Derivados de pentilentetrazol.
WO2013072767A1 (en)	2011-11-18	2013-05-23	Pronova Biopharma Norge As	Compositions and preconcentrates comprising at least one salicylate and omega-3 fatty acid oil mixture
US9585896B2 (en)	2012-04-04	2017-03-07	Pronova Biopharma Norge As	Compositions comprising omega-3 fatty acids and vitamin D for psoriasis, and methods and uses thereof
EP2833740B1 (en)	2012-04-04	2016-09-14	Pronova BioPharma Norge AS	Compositions comprising omega-3 fatty acids and vitamin d for acne vulgaris and/or eczema, and methods and uses thereof
CN104284673B (zh) *	2012-05-14	2018-02-13	帝人株式会社	灭菌组合物
IN2015DN00847A (et)	2012-07-25	2015-06-12	Sarcode Bioscience Inc
US9545446B2 (en)	2013-02-25	2017-01-17	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase and their uses
JP6537980B2 (ja)	2013-02-28	2019-07-03	プロノヴァ・バイオファーマ・ノルゲ・アーエスＰｒｏｎｏｖａＢｉｏＰｈａｒｍａＮｏｒｇｅＡＳ	脂質化合物、トリグリセリドおよび界面活性剤を含む組成物、ならびにその使用方法
AU2014235209B2 (en)	2013-03-15	2018-06-14	Bausch Health Ireland Limited	Guanylate cyclase receptor agonists combined with other drugs
CA2905438A1 (en)	2013-03-15	2014-09-25	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase and their uses
CA2926691A1 (en)	2013-10-10	2015-04-16	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions
US20160151511A1 (en)	2014-12-02	2016-06-02	Antriabio, Inc.	Proteins and protein conjugates with increased hydrophobicity
EP3288550B1 (en)	2015-04-28	2024-06-05	Basf As	Structurally enhanced fatty acids containing sulphur for their use in treating non-alcoholic steatohepatitis
CA3009814A1 (en)	2016-01-11	2017-07-20	Synergy Pharmaceuticals, Inc.	Formulations and methods for treating ulcerative colitis
CA3077011A1 (en)	2017-09-26	2019-04-04	Nanomi B.V.	Method for preparing micro-particles by double emulsion technique
AU2018381124B2 (en)	2017-12-06	2024-06-27	Basf As	Fatty acid derivatives for treating non-alcoholic steatohepatitis

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2010115A1 (de) *	1970-03-04	1971-09-16	Farbenfabriken Bayer Ag, 5090 Leverkusen	Verfahren zur Herstellung von Mikrogranulaten
JPS523342B2 (et) *	1972-01-26	1977-01-27
US3976071A (en) *	1974-01-07	1976-08-24	Dynatech Corporation	Methods of improving control of release rates and products useful in same
US4010125A (en) *	1975-06-12	1977-03-01	Schally Andrew Victor	[D-Trp6 ]-LH-RH and intermediates therefor
US4622244A (en) *	1979-09-04	1986-11-11	The Washington University	Process for preparation of microcapsules
US4384975A (en) *	1980-06-13	1983-05-24	Sandoz, Inc.	Process for preparation of microspheres
US4389330A (en) *	1980-10-06	1983-06-21	Stolle Research And Development Corporation	Microencapsulation process
US4341767A (en) *	1980-10-06	1982-07-27	Syntex Inc.	Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists
US4675189A (en) *	1980-11-18	1987-06-23	Syntex (U.S.A.) Inc.	Microencapsulation of water soluble active polypeptides
PH19942A (en) *	1980-11-18	1986-08-14	Sintex Inc	Microencapsulation of water soluble polypeptides
IE52535B1 (en) *	1981-02-16	1987-12-09	Ici Plc	Continuous release pharmaceutical compositions
CH661206A5 (fr) *	1983-09-23	1987-07-15	Debiopharm Sa	Procede pour la preparation d'un medicament destine au traitement de maladies hormonodependantes.
JPS60100516A (ja) *	1983-11-04	1985-06-04	Takeda Chem Ind Ltd	徐放型マイクロカプセルの製造法
EP0190833B1 (en) *	1985-02-07	1991-03-27	Takeda Chemical Industries, Ltd.	Method for producing microcapsule
JP2551756B2 (ja) *	1985-05-07	1996-11-06	武田薬品工業株式会社	ポリオキシカルボン酸エステルおよびその製造法
US4666704A (en) *	1985-05-24	1987-05-19	International Minerals & Chemical Corp.	Controlled release delivery system for macromolecules
IL79134A (en) *	1985-07-29	1991-06-10	American Cyanamid Co	Continuous release peptide implants for parenteral administration
US4962091A (en) *	1986-05-23	1990-10-09	Syntex (U.S.A.) Inc.	Controlled release of macromolecular polypeptides
US5000886A (en) *	1987-05-26	1991-03-19	American Cyanamid Company	Silicone-hardened pharmaceutical microcapsules and process of making the same
US4800191A (en) *	1987-07-17	1989-01-24	Schally Andrew Victor	LHRH antagonists
US4897268A (en) *	1987-08-03	1990-01-30	Southern Research Institute	Drug delivery system and method of making the same
GB2209937B (en) *	1987-09-21	1991-07-03	Depiopharm S A	Water insoluble polypeptides
US5187150A (en) *	1987-10-14	1993-02-16	Debiopharm S.A.	Polyester-based composition for the controlled release of polypeptide medicinal substances
CH672887A5 (et) *	1987-10-14	1990-01-15	Debiopharm Sa
JP2670680B2 (ja) *	1988-02-24	1997-10-29	株式会社ビーエムジー	生理活性物質含有ポリ乳酸系微小球およびその製造法
DE69024953T3 (de) *	1989-05-04	2005-01-27	Southern Research Institute, Birmingham	Einkapselungsverfahren
HU221294B1 (en) *	1989-07-07	2002-09-28	Novartis Ag	Process for producing retarde compositions containing the active ingredient in a polymeric carrier
CH681425A5 (et) *	1990-11-14	1993-03-31	Debio Rech Pharma Sa
CH679207A5 (et) *	1989-07-28	1992-01-15	Debiopharm Sa
CH683149A5 (fr) *	1991-07-22	1994-01-31	Debio Rech Pharma Sa	Procédé pour la préparation de microsphères en matériau polymère biodégradable.

1991
- 1991-07-22 CH CH2178/91A patent/CH683149A5/fr not_active IP Right Cessation
1992
- 1992-07-15 WO PCT/CH1992/000146 patent/WO1993001802A1/fr active IP Right Grant
- 1992-07-15 CZ CZ1993660A patent/CZ287585B6/cs not_active IP Right Cessation
- 1992-07-15 CH CH882/93A patent/CH683592A5/fr not_active IP Right Cessation
- 1992-07-15 SK SK382-93A patent/SK280612B6/sk unknown
- 1992-07-15 PL PL92298504A patent/PL169387B1/pl not_active IP Right Cessation
- 1992-07-15 BR BR9205375A patent/BR9205375A/pt not_active Application Discontinuation
- 1992-07-15 UA UA93004548A patent/UA35569C2/uk unknown
- 1992-07-15 DE DE4223282A patent/DE4223282A1/de not_active Ceased
- 1992-07-15 DE DE9219084U patent/DE9219084U1/de not_active Expired - Lifetime
- 1992-07-15 HU HU9301186A patent/HU218203B/hu not_active IP Right Cessation
- 1992-07-15 DE DE4223284A patent/DE4223284C2/de not_active Expired - Lifetime
- 1992-07-15 RU RU93004902A patent/RU2103994C1/ru not_active IP Right Cessation
- 1992-07-16 US US07/915,478 patent/US5445832A/en not_active Expired - Lifetime
- 1992-07-20 BE BE9200672A patent/BE1005697A5/fr not_active IP Right Cessation
- 1992-07-20 HR HR920229A patent/HRP920229A2/xx not_active Application Discontinuation
- 1992-07-20 BE BE9200671A patent/BE1005696A3/fr not_active Expired - Fee Related
- 1992-07-21 GR GR920100323A patent/GR1002548B/el not_active IP Right Cessation
- 1992-07-21 SI SI9200152A patent/SI9200152B/sl unknown
- 1992-07-21 AU AU20436/92A patent/AU651711B2/en not_active Ceased
- 1992-07-21 ZA ZA925486A patent/ZA925486B/xx unknown
- 1992-07-21 IT ITBS920093A patent/IT1259892B/it active IP Right Grant
- 1992-07-21 IE IE922366A patent/IE69967B1/en not_active IP Right Cessation
- 1992-07-21 CA CA002074322A patent/CA2074322C/en not_active Expired - Fee Related
- 1992-07-21 FI FI923320A patent/FI105318B/fi not_active IP Right Cessation
- 1992-07-21 NO NO922885A patent/NO304136B1/no not_active IP Right Cessation
- 1992-07-21 NO NO922886A patent/NO304057B1/no unknown
- 1992-07-21 GB GB9215479A patent/GB2257909B/en not_active Expired - Lifetime
- 1992-07-21 JP JP4194313A patent/JP2842736B2/ja not_active Expired - Lifetime
- 1992-07-21 AU AU20437/92A patent/AU652844B2/en not_active Expired
- 1992-07-21 FR FR929208992A patent/FR2680109B1/fr not_active Expired - Fee Related
- 1992-07-21 SE SE9202212A patent/SE512609C2/sv not_active IP Right Cessation
- 1992-07-21 DK DK199200938A patent/DK176218B1/da not_active IP Right Cessation
- 1992-07-21 IT ITBS920092A patent/IT1259891B/it active IP Right Grant
- 1992-07-21 TW TW081105749A patent/TW260610B/zh active
- 1992-07-21 PH PH44682A patent/PH31564A/en unknown
- 1992-07-21 PT PT100713A patent/PT100713B/pt not_active IP Right Cessation
- 1992-07-21 CN CN92109509A patent/CN1054543C/zh not_active Expired - Fee Related
- 1992-07-21 ES ES9201522A patent/ES2037621B1/es not_active Expired - Fee Related
- 1992-07-21 LU LU88150A patent/LU88150A1/fr unknown
- 1992-07-21 NL NL9201309A patent/NL194576C/nl not_active IP Right Cessation
- 1992-07-21 MX MX9204268A patent/MX9204268A/es not_active IP Right Cessation
- 1992-07-21 JP JP19431092A patent/JP3600252B2/ja not_active Expired - Fee Related
- 1992-07-21 ZA ZA925485A patent/ZA925485B/xx unknown
- 1992-07-21 PT PT100712A patent/PT100712B/pt not_active IP Right Cessation
- 1992-07-21 AT AT0148992A patent/AT403348B/de not_active IP Right Cessation
- 1992-07-21 DK DK199200939A patent/DK176219B1/da not_active IP Right Cessation
- 1992-07-21 IL IL102591A patent/IL102591A/xx not_active IP Right Cessation
- 1992-07-21 IL IL102590A patent/IL102590A/xx not_active IP Right Cessation
- 1992-07-21 NZ NZ243643A patent/NZ243643A/en unknown
- 1992-07-21 LU LU88151A patent/LU88151A1/fr unknown
- 1992-07-21 ES ES09201523A patent/ES2050070B1/es not_active Expired - Fee Related
- 1992-07-21 NL NL9201310A patent/NL194577C/nl not_active IP Right Cessation
- 1992-07-21 IE IE922367A patent/IE71199B1/en not_active IP Right Cessation
- 1992-07-21 CA CA002074320A patent/CA2074320C/en not_active Expired - Lifetime
- 1992-07-21 SE SE9202213A patent/SE512670C2/sv not_active IP Right Cessation
- 1992-07-21 GR GR920100322A patent/GR1001446B/el unknown
- 1992-07-21 FI FI923321A patent/FI106925B/fi not_active IP Right Cessation
- 1992-07-21 FR FR9208991A patent/FR2679450B1/fr not_active Expired - Lifetime
- 1992-07-21 AT AT0148892A patent/AT408609B/de not_active IP Right Cessation
- 1992-07-21 GB GB9215480A patent/GB2257973B/en not_active Expired - Fee Related
1993
- 1993-03-22 KR KR1019930700851A patent/KR930702018A/ko not_active IP Right Cessation
1994
- 1994-03-16 US US08/210,097 patent/US5637568A/en not_active Expired - Fee Related
- 1994-11-21 EE EE9400282A patent/EE03014B1/et unknown

Also Published As

Publication number	Publication date
JP3600252B2 (ja)	2004-12-15
IL102591A0 (en)	1993-01-14
SE512609C2 (sv)	2000-04-10
IL102590A0 (en)	1993-01-14
CZ66093A3 (en)	1994-01-19
DK176219B1 (da)	2007-02-26
FI923321A0 (fi)	1992-07-21
ITBS920093A1 (it)	1994-01-21
AU651711B2 (en)	1994-07-28
CA2074320A1 (en)	1993-01-23
TW260610B (et)	1995-10-21
SI9200152A (en)	1993-03-31
PT100712A (pt)	1993-10-29
AT408609B (de)	2002-01-25
ATA148892A (de)	2001-06-15
DK93992D0 (da)	1992-07-21
KR930702018A (ko)	1993-09-08
CA2074322C (en)	2003-04-08
NO922886L (no)	1993-01-25
PT100713B (pt)	1999-07-30
GB9215480D0 (en)	1992-09-02
AU652844B2 (en)	1994-09-08
GB2257909B (en)	1996-01-10
SI9200152B (sl)	1998-06-30
HU218203B (hu)	2000-06-28
FI106925B (fi)	2001-05-15
IE922366A1 (en)	1993-01-27
IE71199B1 (en)	1997-02-12
NO922886D0 (no)	1992-07-21
GR1001446B (el)	1993-12-30
SK38293A3 (en)	1993-08-11
IT1259891B (it)	1996-03-28
GB2257909A (en)	1993-01-27
SE512670C2 (sv)	2000-04-17
CN1054543C (zh)	2000-07-19
GB2257973B (en)	1996-02-28
PL298504A1 (en)	1994-01-10
DE4223284A1 (de)	1993-01-28
NL9201310A (nl)	1993-02-16
CN1070344A (zh)	1993-03-31
DK93892D0 (da)	1992-07-21
BR9205375A (pt)	1994-03-08
UA35569C2 (uk)	2001-04-16
NO922885L (no)	1993-01-25
FI923321A (fi)	1993-01-23
CH683149A5 (fr)	1994-01-31
FR2680109A1 (fr)	1993-02-12
MX9204268A (es)	1994-03-31
IL102591A (en)	1997-06-10
AU2043692A (en)	1993-01-28
FI105318B (fi)	2000-07-31
IE922367A1 (en)	1993-01-27
GB9215479D0 (en)	1992-09-02
DK93892A (da)	1993-01-23
NL9201309A (nl)	1993-02-16
NO304136B1 (no)	1998-11-02
SE9202212L (sv)	1993-01-23
WO1993001802A1 (fr)	1993-02-04
FR2680109B1 (fr)	1994-09-02
HRP920229A2 (en)	1996-04-30
PT100713A (pt)	1993-08-31
ITBS920093A0 (it)	1992-07-21
US5637568A (en)	1997-06-10
ES2037621A1 (es)	1993-06-16
ZA925486B (en)	1993-04-28
PT100712B (pt)	1999-07-30
IT1259892B (it)	1996-03-28
NL194577C (nl)	2002-08-05
DE4223284C2 (de)	1997-07-31
JPH05221855A (ja)	1993-08-31
NL194576C (nl)	2002-08-05
DE9219084U1 (de)	1997-09-25
DK176218B1 (da)	2007-02-26
NL194576B (nl)	2002-04-02
CA2074322A1 (en)	1993-01-23
IE69967B1 (en)	1996-10-16
ATA148992A (de)	1997-06-15
LU88151A1 (fr)	1993-02-15
NO304057B1 (no)	1998-10-19
ZA925485B (en)	1993-04-28
FI923320A (fi)	1993-01-23
ES2050070A1 (es)	1994-05-01
DE4223282A1 (de)	1993-01-28
HUT64234A (en)	1993-12-28
FR2679450A1 (fr)	1993-01-29
LU88150A1 (fr)	1993-02-15
JPH06172208A (ja)	1994-06-21
AU2043792A (en)	1993-01-28
SK280612B6 (sk)	2000-05-16
IL102590A (en)	1997-07-13
NZ243643A (en)	1993-10-26
GR920100323A (el)	1993-05-24
GR1002548B (el)	1997-01-28
HU9301186D0 (en)	1993-07-28
JP2842736B2 (ja)	1999-01-06
CZ287585B6 (cs)	2000-12-13
ITBS920092A0 (it)	1992-07-21
ES2050070B1 (es)	1994-10-01
US5445832A (en)	1995-08-29
DK93992A (da)	1993-01-23
SE9202213L (sv)	1993-01-23
NO922885D0 (no)	1992-07-21
AT403348B (de)	1998-01-26
RU2103994C1 (ru)	1998-02-10
SE9202213D0 (sv)	1992-07-21
FI923320A0 (fi)	1992-07-21
ES2037621B1 (es)	1994-02-01
PL169387B1 (pl)	1996-07-31
BE1005696A3 (fr)	1993-12-21
NL194577B (nl)	2002-04-02
FR2679450B1 (fr)	1995-06-09
SE9202212D0 (sv)	1992-07-21
GB2257973A (en)	1993-01-27
PH31564A (en)	1998-11-03
CH683592A5 (fr)	1994-04-15
BE1005697A5 (fr)	1993-12-21
ITBS920092A1 (it)	1994-01-21
CA2074320C (en)	1999-04-06

Publication	Publication Date	Title
EE03014B1 (et)	1997-08-15	Pikendatud ja kontrollitud vabanemisega peptiidi sisaldav ravimaine kompositsioon ja selle valmistamismeetod
NO20013566D0 (no)	2001-07-19	Farmasöytisk preparat med regulert frigjöringsvirkning
NO924183D0 (no)	1992-10-29	Farmasoeytiske preparater med regulert frigjoering
IT8820145A0 (it)	1988-04-08	Composizione farmaceutiche a rilascio controllato e procedimento per la loro preparazione.
DE69704712D1 (de)	2001-06-07	Tablette mit gesteuerter freisetzung von alfuzosinhydrochlorid
DE69506086D1 (de)	1998-12-24	Zusammensetzung mit gesteuerter freisetzung
DE69127354D1 (de)	1997-09-25	Prothese
NO973446L (no)	1997-09-26	Forbindelser med veksthormonfrigjörende egenskaper
FI943168A (fi)	1995-01-02	Opioidiformulaatioita, joissa on pitkitetty säädelty vapautuminen
EE03108B1 (et)	1998-08-17	Farmatseutiline kompositsioon
ZA894020B (en)	1990-02-28	Controlled release pharmaceutical formulation
DE59003337D1 (de)	1993-12-09	Pressling mit retardierter Wirkstofffreisetzung.
NO975992L (no)	1998-02-20	Forbindelser med veksthormonfrigjörende egenskaper
FI962646A (fi)	1996-06-26	Adsorptiomateriaali ja menetelmä
NO20001375L (no)	2000-03-16	Legemiddelformulering med kontrollert virkestoffrigivning
EE03015B1 (et)	1997-08-15	Ravimpreparaat ja selle valmistamise protsess
FI940775A0 (fi)	1994-02-18	alfa-fenyyli-isoseriinijohdannaisten valmistusmentelmä ja niiden käyttö
BR9305261A (pt)	1994-07-05	Composição implantável com liberação controlada
DE69518193D1 (de)	2000-09-07	Präparat mit verzörgerter Wirkstoffabgabe
FI894323A (fi)	1990-03-15	Antimikrobiaalinen ainekoostumus, menetelmä ja käyttö
FI954348A (fi)	1995-11-15	Säädetysti vapauttava alumiinia sisältävä farmaseuttinen valmiste
NO942228D0 (no)	1994-06-14	Ipsapiron-legemiddeltilberedning
FI941800A0 (fi)	1994-04-19	Psoriasiksen vastaiset lääkeainekoostumukset ja menetelmä niiden valmistamiseksi
FI910804A (fi)	1992-08-20	Masugnsslaggbetong med hoeg haollfasthet
IT1224244B (it)	1990-09-26	Composizione farmaceutica anoressizzante comprendente 5-idrossitrpofano